An observational study in Terminal Care, sponsored by Erasmus Medical Center. Completed at 11 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by Erasmus Medical Center · Observational
The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. The primary outcome for the cohort study is a descriptive assessment of the concerns, expectations and preferences around dying and end-of-life care of patients and their relatives, in different settings and cultures..
Rationale: In the EU about 4 million people yearly die from a chronic illness. Many of these people die in pain or distress. Care for dying patients and their close relatives is often suboptimal.
Objective: To contribute to high-quality personalized care at the end of life by:
Main study endpoints: The primary outcome for the cohort study is a descriptive assessment of patients' concerns, expectations and preferences around dying and end-of-life care, at baseline and after one month of follow-up.
Potential risks and benefits associated with participation: The study population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening or stigmatizing participants. If patients feel burdened by participating in the study, they are encouraged to indicate that. The investigators will develop a protocol for researchers and interviewers to address such situations.
Erasmus Medical Center is the lead sponsor of 466 studies on the registry; 179 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All competent adult patients with an estimated life expectancy of six months or less are eligible, regardless of their diagnosis, gender or age, or place of residence, and their relatives
Inclusion Criteria patients:
General SPICT indicators:
Disease-specific SPICT indicators:
Cancer:
Neurological disease:
Heart/vascular disease:
Respiratory disease:
Kidney disease:
Liver disease:
Dementia/ frailty:
Other conditions:
o Deteriorating and at risk of dying with other conditions or complications that are not reversible; any treatment available will have a poor outcome
Exclusion Criteria patients:
Inclusion Criteria relatives:
Exclusion Criteria relatives:
Patients in the last phase of life and their families
Other: Observational study
No intervention involved
Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)
Self developed questions, adapted from the Serious Illness Conversation Guide and the AEOLI questionnaire.
Time frame: Baseline
Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)
Self developed questions, which were inspired by the Serious Illness Conversation Guide and the AEOLI questionnaire.
Time frame: One month of follow-up
Edmonton Symptom Assessment Scale (range 0-10, with higher score meaning worse outcome)
Symptoms
Time frame: At baseline and after one month of follow-up
European Organisation for Research and Treatment of Cancer Quality of Life C15-Palliative Care questionnaire, quality of life item (range 1-7, with higher score indicating better outcome)
Quality of life
Time frame: At baseline and after one month of follow-up
EuroQol-5d questionnaire (range 1-5 per item, with higher score indicating worse outcome)
Quality of life
Time frame: At baseline and after one month of follow-up
ICECAP Supportive Care Measure (range 1-4 per item, with higher score indicating worse outcome)
Experience of support
Time frame: At baseline and after one month of follow-up
Use of medical interventions (hospitalisation, medication, surgery, other interventions)
Retrospective assessment for patients who die during follow-up of medical interventions in the last week of patients' life, using a self-developed checklist
Time frame: One week
Bereaved relatives' experiences
International Care of the dying questionnaire (descriptive), Hogan Grief Reaction Checklist (despair (13 items) and personal growth (12 items) scales, range 1-5 per item)
Time frame: 8-10 weeks post-bereavement
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erasmus Medical Center